Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents

NCT02517892 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT02517892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02517892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Not applicable
Overall status
Completed
Start date
December 18, 2014
Completion date
March 31, 2025
Enrollment
1,500 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic oncogen-driven cancer